Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

February 14, 2023

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

April 18, 2022

William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each space.

February 07, 2022

Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.

January 21, 2022

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.

January 11, 2022

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.

January 10, 2022

The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.

November 18, 2021

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

October 15, 2021

Mary F. Mulcahy, MD, discusses the key takeaways from the ongoing EPOCH trial in patients with colorectal cancer and liver metastases. 

August 06, 2021

TheraSphere Y-90 glass microspheres offer a precision medicine technique aimed at delivering high-dose radiation directly to tumors.

June 25, 2021

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

April 23, 2021

William Gradishar, MD, discusses the phase 2 data evaluating the activity with IV cetirizine and its potential use in patients with breast cancer.

April 19, 2021

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

April 19, 2021

Jyoti D. Patel, MD, discusses the evolving use of osimertinib in EGFR-mutant NSCLC and emerging targeted agents for patients with EGFR exon 20 insertion mutations.

December 17, 2020

Massimo Cristofanilli, MD, highlights the introduction of CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib, which has been a significant addition to the hormone receptor–positive, HER2-negative breast cancer armamentarium.

November 10, 2020

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

October 28, 2020

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

October 21, 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

October 20, 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

October 15, 2020

Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

October 09, 2020

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.